The fibroblast growth factor receptor signaling pathway as a mediator of intrinsic resistance to EGFR-specific tyrosine kinase inhibitors in non-small cell lung cancer
Authors:
- 1 August 2009
- journal article
- review article
- Published by Elsevier in Drug Resistance Updates
- Vol. 12 (4-5) , 95-102
Abstract
No abstract availableKeywords
This publication has 87 references indexed in Scilit:
- Somatic mutations affect key pathways in lung adenocarcinomaNature, 2008
- Drug-sensitiveFGFR2mutations in endometrial carcinomaProceedings of the National Academy of Sciences, 2008
- Oncogenes and CancerNew England Journal of Medicine, 2008
- MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinibProceedings of the National Academy of Sciences, 2007
- Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromesOncogene, 2007
- Erlotinib in Previously Treated Non–Small-Cell Lung CancerNew England Journal of Medicine, 2005
- Erlotinib in Lung Cancer — Molecular and Clinical Predictors of OutcomeNew England Journal of Medicine, 2005
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- Cell adhesion and signalling by cadherins and Ig-CAMs in cancerNature Reviews Cancer, 2004
- The Hallmarks of CancerCell, 2000